Je was op zoek naar: proarrhythmic (Engels - Maltees)

proarrhythmic potential
potenzjal proarritmiku

proarrhythmic effects:
effetti pro-arritmiċi:

a proarrhythmic potential of bosutinib cannot be ruled out.
potenzjal pro-arritmiku ta’ bosulif ma jistax jiġi eskluż.

defitelio might be considered free of proarrhythmic toxicity related to qt changes.
defitelio jista' jitqies ħieles minn tossiċità proarritmika relatata ma' tibdiliet fil-qt.

voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as
voriconazole għandu jingħata b’kawtela lil pazjenti li għandhom kondizzjonijiet potenzjalment proarritmiċi, bħal:

voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as:
voriconazole għandujingħata b'kawtela lil pazjenti li għandhom kondizzjonijiet potenzjalment proarritmiċi, bħal

targeted effects on atrial tissue coupled with block of late sodium current suggests that vernakalant has a low proarrhythmic potential.
l-effetti mmirati fuq it-tessut atrijali flimkien mal-imblokk ta’ sodju tardiv jissuġġerixxu li vernakalant għandu potenzjal proarritmiku baxx.

no proarrhythmic effects were observed in 3,162 patients treated with ranexa based on 7-day holter monitoring in the merlin-timi 36 study.
l-ebda effetti proarritmiċi ma kienu osservati fi 3,162 pazjent ikkurati b’ranexa abbażi ta’ monitoraġġ holter ta’ 7 ijiem fl-istudju merlin-timi 36.

voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as  congenital or acquired qt-prolongation  cardiomyopathy, in particular when heart failure is present  sinus bradycardia  existing symptomatic arrhythmias  concomitant medication that is known to prolong qt interval electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.2).
voriconazole għandu jingħata b' kawtela lil pazjenti li għandhom kondizzjonijiet potenzjalment proarritmiċi, bħal  titwil konġenitu jew akkwiżit tal- qt  kardjomijopatija, b' mod partikolari meta jkun hemm insuffiċjenza tal- qalb  taħbit tal- qalb bil- mod ħafna  arritmiji sintomatiċi eżistenti  medikazzjoni konkomitanti li hija magħrufa li ttawwal l- intervall qt disturbi elettroliti bħal ipokalimja, hypomagnesaemia u ipokalċimja għandhom jiġu mmonitorjati u korretti, jekk ikun meħtieġ, qabel ma tinbeda u waqt terapija b' voriconazole (ara sezzjoni 4. 2).